Back to INEXION
Investor Overview
Seed Stage · Open to Aligned Investors · The Longevity Data Company

The registry no incumbent
can replicate — and the platforms it unlocks.

Flatiron proved the outcome — irreplaceable data plus the workflow layer, $1.9B to Roche. Verana proved the mechanism, and stalled without one. INEXION is engineered for the Flatiron conditions in longevity: a clinical-grade longitudinal registry no claims platform can replicate, the clinic software that generates it, and the analytics platforms stacked on top.

Request the Investor Brief See the Model
Q3’26
Target seed close · family-office led · terms in the Investor Brief
$2.7B
RWD licensing market today · $7.1B by 2033 · zero longevity coverage
25K+
Patient records · Gate 2 Series A trigger (May 2027)
The Opportunity

A category that doesn't exist yet —
built on data nobody else can see.

Longevity care is delivered through thousands of independent cash-pay practices serving high-income patients with biologics, hormone optimization, metabolic interventions, and biomarker-driven protocols. These practices operate outside hospital systems and outside insurance networks — generating zero claims data.

The most valuable cohort in healthcare is structurally invisible to every legacy data platform. IQVIA, Komodo, Symphony, and the rest are claims-first by architecture — they have no pipeline into this setting. The data does not exist in any licensable form.

INEXION is building it. The registry integrates three data layers under a unified schema: a public-data spine (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare), private partner contributions from longevity clinics and telehealth platforms, and medical society partnerships (A4M, Longevity Docs). Schema enforced at the integration layer. Capital-light by design — no acquisition, no operational build-out. The moat is in the data flow.

Why a better-funded competitor cannot catch up: capital cannot buy longitudinal time or retroactive consent, partner exclusivity and schema switching costs lock the supply side, a two-sided benchmarking flywheel compounds with every clinic added, and the first FDA-qualified aging biomarker owns a regulatory lane money alone cannot shortcut.

$128B+
Data-generating economy — the source pool, not the TAM
$2.7B
Reference market — RWD licensing today (→ $7.1B by 2033)
~5K
Independent longevity clinics — the data source pool
Revenue Architecture

One revenue line.
Built for valuation.

Single revenue line: data licensing. Pharma, biotech, and CROs pay to access a clinical-grade longevity registry that no claims-based platform can build. Platform multiples (15–20×+) from inception. Products, not headcount.

01
Pharma HEOR Data Licensing
De-identified longitudinal registry licensed to pharma HEOR teams running longevity-adjacent programs (GLP-1s, senolytics, NAD+ pathway modulators). $150K–$400K per study. Buyers: Eli Lilly, Novo Nordisk, Pfizer, Amgen. The primary value-creation engine — re-rates the business to platform multiples (15–20×+) at scale.
Revenue characteristics
80%+ margin $150K–$400K / study 15–20×+ multiple
02
Real World Evidence Studies
Sponsor-funded RWE through the partner network — registry data fees plus protocol-based study fees. Comparator data, biomarker validation, label expansion support. $75K–$500K per study. Buyers: Insilico Medicine, Life Biosciences, Rubedo Life Sciences, longevity biotech R&D.
Revenue characteristics
75–85% margin Sponsor-funded Network-effect
03
Partner-Network Site Identification
Site identification, qualification, and contracting fees from sponsors and CROs (Parexel, Syneos, ICON) — without operating the sites. $50K–$250K per matched site, plus $100K–$500K trial-network access fees. No legacy network operates in longevity — Advarra and WCG run through hospital systems that don't see this cohort.
Revenue characteristics
60–70% margin $50K–$250K / site Uncontested category
04
AI/ML Training Datasets
Multimodal longitudinal longevity data — currently unbuyable as a training corpus. Buyers: AI/ML programs across pharma and biotech, plus data science teams at Tempus, Saama, and similar firms building predictive models. $200K–$500K per year. Highest-margin revenue line.
Revenue characteristics
90%+ margin 15–20× multiple Unbuyable today
The Data Asset

Every partner added makes
the registry more valuable.

INEXION builds the registry through a partnership-led network — telehealth platforms, longevity clinics, EHR partners, medical societies — all contributing under a unified schema. No acquisition CapEx. No operational build-out. Capital flows entirely to data infrastructure and partnership BD. Cash-pay longevity patients are structurally invisible to every claims-based platform. Schema enforced at the integration layer means data quality compounds with every partner added. At maturity the registry is publishable, licensable, and the foundation for clinical research partnerships.

Comparable Outcomes

Validated by precedent.

The data-platform comp set has consistently rewarded the entity that built the dataset incumbents could not. INEXION is the longevity entry.

Flatiron Health
Oncology EHR →
$1.9B Roche acq.
Verana Health
Specialty registry →
mechanism proven · no exit
Komodo Health
Claims data →
$3.3B valuation
INEXION
Longevity →
Category does not yet exist
10K+
Patient Records · Seed Year 1
Public-data spine integrated (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare). Healthspan LOI executed (Feb 2026). AgelessRx in late-stage negotiation. Reya.ai named Track 2 EHR partnership lead — term sheet target Oct 2026. Registry schema v1 in progress; first publishable cohort analyses targeted Q4 2026.
25K+
Patient Records · Gate 2 Series A Trigger
Gate 2 composite (May 2027): $500K ARR + 2+ active LOIs + 25K patient records + 3+ Type-1 partners operational. Series A raise: $10–15M, institutional and strategic investors.
100K+
Patient Records · Scale
50+ partners across clinic, telehealth, and EHR networks. Multiple licensing contracts active. Registry publishable, licensable, foundation for clinical research and AI/ML training contracts.
Market Timing

Why this.
Why now.

The conditions that make INEXION possible — and urgent — have converged in the last 24 months.

01
First-mover advantage on longevity data is unclaimed
Longevity clinics, telehealth platforms, and patients are generating outcomes data right now — none of it is being captured in structured, multi-source form. In five years, someone will have built the longevity equivalent of Flatiron. INEXION is positioned to be that someone.
02
Capital is rotating into longevity
Longevity biotech funding surged to $554M in Q4 2025 alone — a 900%+ increase over Q3. Eli Lilly, OpenAI, and Manulife all made direct longevity investments in the last year. The buyers for the registry are funding the field that generates the data.
03
The registry-data category is being formally established
The federal government committed $144M to build healthspan biomarker and registry research. Nature Aging (DOI: 10.1038/s41514-025-00313-1) published a formal biomarker standardization framework calling for pre-competitive shared data tools across multi-site research. INEXION is the physician-embedded delivery layer this framework requires.
04
Incumbent platforms are structurally locked out
Cash-pay longevity is invisible to every claims-based data platform. IQVIA, Komodo, Symphony have no mechanism to reach this cohort — and you cannot retrofit a longitudinal cash-pay registry. The window to build it the right way, with schema control at the integration layer, is open now.
Beyond the Registry
The registry is the first product. The data foundation underneath it unlocks adjacent analytics platforms — payer ROI models, FDA biomarker qualification — and each activation is a re-rating event. Federal health-analytics engagements add a non-dilutive parallel path. Full detail in the Investor Brief.
Capital Strategy

Designed to compound.
Not to exit on a schedule.

Seed syndicate forming — terms in the Investor Brief. Series A ($10–15M): led by institutional and strategic healthcare investors. Open to family offices, angels, and venture funds with long time horizons and conviction about the longevity data category.

We are deliberately avoiding venture capital at the seed stage. VC introduces exit pressure and quarterly performance anxiety incompatible with building a multi-decade compounding platform. The right capital comes from investors with long time horizons and genuine conviction.

Use of proceeds is capital-light by design: 54% to team and operations (~$60K/month burn × 18 months), 30% to data platform engineering, 12% to partnership integration and pharma BD, 4% reserve. No acquisition CapEx. No operational build-out.

Series A triggers on Gate 2 composite (May 2027): $500K ARR + 2+ active LOIs + 25K patient records + 3+ Type-1 partners operational. Raise: $10–15M, institutional and strategic investors. Single-line data licensing economics in the mold of Flatiron, Verana, Komodo, and IQVIA.

Open Seed Round Q3 2026 Target Close Terms in the Investor Brief SAFE — Extendable Aligned Investors Institutional + Strategic at Series A
Milestone Roadmap
Seed · 2026
Registry Stand-Up
Public-data spine integrated. Healthspan + additional partner data exchanges live. Schema v1 deployed. First HEOR conversations advanced. Pre-revenue.
Build · 2027
Series A Trigger
6+ partner integrations live. Registry at 25K+ patient records. First HEOR licensing contract signed. Gate 2 composite trigger hit. Series A raise begins ($10–15M).
Series A · Q3–Q4 2027
Platform Activation
Multiple licensing contracts. Trial site network forming. Data licensing engine active across 4 buyer segments.
Scale · 2028+
Registry at Scale
50+ partners. 100K+ patient records. AI/ML training contracts live. Platform multiple re-rating. $500M–$1B registry floor — the platform ceiling sits beyond it.
Leadership

Operator-built. Clinically grounded. Ready to scale.

Ian Wendt
Ian Wendt
Founder & CEO
Three decades of biopharma commercial leadership. Most recently CCO at Jaguar Health. Deep expertise in launch strategy, market access, and business development. Co-host of The RealPharma Podcast. MBA, Dalhousie University.
Gilead SciencesBoehringer IngelheimJaguar Health
Na-Ri Oh
Na-Ri Oh, MD
Co-Founder & COO
Physician and global biopharma executive who bridges clinical medicine and commercial strategy. Practiced as an Infectious Disease physician before leading commercial and strategic planning initiatives across HIV, viral hepatitis, and liver disease at Boehringer Ingelheim and Gilead Sciences. Now leads INEXION's Department of Defense partnership as company liaison. Co-host of The RealPharma Podcast. Angel investor and LP at Black Canyon Ventures and VC Fellow at the Material Change Institute. MD, Heidelberg University.
Gilead SciencesBoehringer Ingelheim
Nirav Vira
Nirav Vira
Chief Technology Officer
25+ years in healthcare data and AI-powered SaaS. Built a 50M-patient data lake at Verana Health. CTO of WithMe Health. Built the enterprise analytics infrastructure at Change Healthcare. B.E., University of Mumbai.
Verana HealthChange Healthcare
Raghav Sehgal
Raghav Sehgal, PhD
Chief Scientific Officer
Forbes 30 Under 30 (Healthcare, 2025). Yale Research Faculty in biological aging and epigenomics — trained under Morgan Levine (PhenoAge co-author; SYMPHONYAge, Nature). Director, Yale Longevity Clinic. 18+ peer-reviewed publications. Primary clinical credibility for the registry's research-grade data and pharma BD pipeline.
Yale UniversityForbes
For Investors
Request the investor brief.
We're working with a select group of aligned investors in our seed round — family offices, angels, and venture funds. Series A ($10–15M) will be led by institutional and strategic healthcare investors. If you have a long time horizon and conviction about the longevity data category, we'd like to have a conversation.
Request the Investor Brief View Registry Details